IDEX Corporation closed out 2025 with strong performance in the fourth quarter, driven by record sales and orders, particularly in the Health & Science Technologies segment due to increasing demand for AI-related projects. Despite a challenging demand environment in other segments, the company's strategic execution delivered visible results and improved operational metrics.
Record sales of $899 million were achieved in Q4 2025, marking a 4% increase on a reported basis and 1% organically.
Record orders of $979 million in Q4 2025, up 20% on a reported basis and 16% organically, primarily due to strength in HST.
Diluted EPS increased by 6% to $1.71, and adjusted diluted EPS rose by 3% to $2.10 in Q4 2025.
The company utilized $73 million for share repurchases during the fourth quarter, demonstrating commitment to shareholder returns.
IDEX projects continued growth for the full year and first quarter of 2026, with organic sales and adjusted diluted EPS expected to increase.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance